Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wuttipong Masraksa has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Self-Emulsifying Formulation of Huperzia carinata Extract to Improve Huperzine A Solubility for Therapeutic Efficacy Enhancement in Parkinsonian Mice

    by Namfa Sermkaew, Nuttapon Songnaka, Wuttipong Masraksa, Amit Jaisi, Yosita Yongyuen, Pannatorn Buntha, Nadiah Syafiqah Nor Azman, Juntratip Jomrit, Phetcharat Boonruamkaew

    Huperzine A (HupA), a sesquiterpene alkaloid isolated from Huperzia serrata, is clinically applied in China for Alzheimer’s disease and in the United States as a dietary supplement. In Thailand, Huperzia carinata (H. carinata) is an alternative and the richest natural source of HupA. However, poor solubility and low oral bioavailability restrict its therapeutic application. This study aimed to develop a self-emulsifying drug delivery system (SEDDS) to improve the solubility, dissolution, and efficacy of HupA from H. carinata extract in a mouse model of Parkinson’s disease (PD). The optimized SEDDS consisted of oleic acid (20%), polyethylene glycol-40 hydrogenated castor oil (70%), and propylene glycol (10%), containing 10% H. carinata extract. The HupA-loaded SEDDS displayed efficient self-emulsification, producing droplet sizes of 175.2 ± 8.3 nm to 253.4 ± 2.8 nm upon dilution in water. The SEDDS promoted rapid dissolution, achieving approximately 70% HupA release within 5 min and near-complete dissolution (100%) by 120 min in both gastric and intestinal media. In vitro, the SEDDS displayed significantly superior antioxidant and anti-inflammatory activities compared with the unformulated extract (p < 0.001). In vivo, MPTP-induced Parkinsonian mice receiving SEDDS containing HupA (0.75 and 1.00 μmol/kg body weight) showed significant improvements in locomotor function and motor coordination compared with both vehicle- and blank-SEDDS-treated groups (p < 0.001) at days 3 and 7 after MPTP induction. Biochemical assessments revealed declined malondialdehyde and nitrite levels in cortical and striatal brain tissues compared with the vehicle- and blank-SEDDS-treated groups (p < 0.05). Molecular studies confirmed that HupA-loaded SEDDS increased tyrosine hydroxylase and decreased tumor necrosis factor-α expression compared with the vehicle-treated group (p < 0.001) while protecting dopaminergic neurons in immunohistochemistry, indicating neuroprotective and antineuroinflammatory effects. The SEDDS formulation may represent a promising drug delivery system for the clinical application of HupA in PD and potentially other neurodegenerative disorders. This study contributes to Sustainable Development Goal 3 (good health and well-being) by developing neuroprotective formulations for neurodegenerative diseases.

  • Open Access

    Suk-SaiYasna Remedy, a Traditional Thai Medicine, Mitigates Stress-Induced Cognitive Impairment via Keap1-Nrf2 Pathway

    by Wuttipong Masraksa, Supawadee Daodee, Orawan Monthakantirat, Chantana Boonyarat, Charinya Khamphukdee, Pakakrong Kwankhao, Abdulwaris Mading, Poowanarth Muenhong, Juthamart Maneenet, Suresh Awale, et al.

    Suk-SaiYasna (SSY) is a well-documented traditional Thai herbal formula in the Royal Scripture of King Narai’s Traditional Medicine. SSY contains Cannabis sativa leaves as a key ingredient and has traditionally been used to promote sleep, alleviate stress-related symptoms, and stimulate appetite. This study aimed to investigate the neuroprotective effects of SSY in a mouse model of unpredictable chronic mild stress (UCMS)-induced cognitive impairment and explore the underlying mechanisms, particularly antioxidant enzyme pathways. Behavioral tests, including the Y-maze test, novel object recognition test, and Morris water maze test, demonstrated that UCMS-exposed mice exhibited cognitive impairment compared to non-stress mice. However, SSY treatment significantly improved learning and memory performance in UCMS-exposed mice. Mechanistic studies revealed that SSY reduced lipid peroxidation in the hippocampus and frontal cortex, key brain regions affected by chronic stress. Furthermore, UCMS significantly reduced the activity of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT), whereas SSY treatment restored their activity, indicating antioxidative and neuroprotective effects in vivo. Gene expression analysis further revealed that SSY regulates oxidative stress via the Nrf2/Keap1 signaling pathway. In vitro studies using 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay confirmed the radical scavenging activities of SSY and its herbal components, demonstrating significant antioxidant potential. Phytochemical analysis identified delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabinolic acid A, and cannabinoids as bioactive compounds in SSY, along with potent antioxidants such as gallic acid, myricetin, myristicin, piperine, costunolide, and gingerol. These findings suggest that the SSY formula mitigates UCMS-induced cognitive function through its antioxidant properties via multiple pathways, including radical scavenging activities, modulating the Nrf2-Keap1 pathway, inducing the expression of HO-1, NQO1 mRNAs, and other antioxidant enzymes. This work bridges traditional Thai medicine with modern neuropharmacology.